Mark Belkin, MD, explains why HFpEF goes undiagnosed, how MRA evidence should guide therapy, and what's next for AI-driven ...

Even with MINT's mandatory steroid taper, inebilizumab still cut exacerbation and rescue therapy rates versus placebo, said ...

Precision medicine approaches for chronic obstructive pulmonary disease (COPD) are lagging, creating gaps in care and leaving ...

Sixteen weeks of dupilumab improved lesion severity scores 59.8% vs 15.2% with placebo in 94 adults with moderate-to-severe ...

Standardizing notification workflows and reimbursing prenatal risk screening increased data completeness, reduced ...

Lalan Wilfong, MD, discusses how model assumptions, cohort design, and risk adjustment shape performance and accountability ...

Keith Kaye, MD, MPH, breaks down the institutional gaps, from antibiotic overuse to hand hygiene fatigue, that let ...

In part 1 of an interview with The American Journal of Managed Care® ( AJMC®) at the Community Oncology Alliance (COA) Payer ...

Terminology shifts to “decompensated heart failure,” introducing an initial–stabilization–pre/postdischarge framework and ...

Define the “last-mile equity gap” as the unmeasured distance between care delivery and patient comprehension, which can ...

Christos Vaklavas, MD, discussed barriers limiting rural oncology access and challenges to adopting resource-intensive ...

Biomarker testing remains a cornerstone of precision oncology, particularly for non–small cell lung cancer, yet obstacles ...